VVOS – vivos therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Vivos Therapeutics, Inc. (NASDAQ: VVOS) had its "buy" rating re-affirmed by analysts at Ascendiant Capital Markets. They now have a $6.60 price target on the stock.
Vivos Therapeutics, Inc. (NASDAQ: VVOS) had its price target lowered by analysts at Alliance Global Partners from $8.25 to $6.00. They now have a "buy" rating on the stock.
Vivos Therapeutics Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag [Yahoo! Finance]
Vivos Therapeutics Reports Third Quarter 2024 Financial Results and Provides Operational Update [Yahoo! Finance]
Vivos Therapeutics Reports Third Quarter 2024 Financial Results and Provides Operational Update
Form SC 13G/A Vivos Therapeutics, Inc. Filed by: ARMISTICE CAPITAL, LLC
Form 8-K Vivos Therapeutics, Inc. For: Nov 14
Form 10-Q Vivos Therapeutics, Inc. For: Sep 30
Form SC 13G/A Vivos Therapeutics, Inc. Filed by: Ionic Ventures, LLC
Form DEFA14A Vivos Therapeutics, Inc.
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.